<DOC>
	<DOCNO>NCT00728845</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , hydroxychloroquine , carboplatin , paclitaxel work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Bevacizumab may also stop growth tumor cell block blood flow tumor . Giving hydroxychloroquine together carboplatin , paclitaxel bevacizumab may kill tumor cell . PURPOSE : This phase I/II trial study side effect best dose hydroxychloroquine give together carboplatin , paclitaxel , bevacizumab see well work treat patient recurrent advance non-small cell lung cancer .</brief_summary>
	<brief_title>Hydroxychloroquine , Carboplatin , Paclitaxel , Bevacizumab Recurrent Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine recommended phase II dose hydroxychloroquine carboplatin combination paclitaxel bevacizumab patient advanced recurrent non-small cell lung cancer . ( Phase I ) - To assess antitumor activity , measure tumor response rate , regimen patient . ( Phase II ) Secondary - To measure time progression , progression-free survival , overall survival patient . - To assess incidence toxicity regimen patient . OUTLINE : This multicenter study . This phase I , dose-escalation study carboplatin hydroxychloroquine follow phase II study . Patients receive paclitaxel IV 3 hour , carboplatin IV 15-30 minute , bevacizumab IV 90 minute day 1 oral hydroxychloroquine day 1-21 . Treatment repeat every 21 day total 4 course . Patients receive bevacizumab IV 30-90 minute every 21 day oral hydroxychloroquine daily 1 year absence disease progression unacceptable toxicity . After completion study therapy , patient follow every 6 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Hydroxychloroquine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm advanced nonsmall cell lung cancer , meet follow criterion : Recurrent disease No component squamous cell carcinoma Mixed tumor categorize predominant cell type No mixed histology small cell component Diagnosis establish metastatic tumor aspirate biopsy ( sputum cytology alone ) meet 1 follow stag criterion : Stage IIIB disease malignant pleural effusion Stage IV disease Measurable disease More 1 year since postoperative adjuvant therapy previously resect nonsmall cell lung cancer evidence disease progression No known CNS metastases CT scan brain MRI within past 28 day PATIENT CHARACTERISTICS : ECOG performance status 01 ANC ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 9 g/dL Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) ( ≤ 2 time ULN liver function test abnormality patient Gilbert disease ) AST/ALT ≤ 2.5 time ULN ( ≤ 5 time ULN presence liver metastasis ) Alkaline phosphatase ≤ 2.5 time ULN Creatinine ≤ 1.5 time ULN OR creatinine clearance ≥ 60 mL/min INR ≤ 1.5 aPTT normal Urine protein : creatinine ratio &lt; 1.0 OR urine protein ratio &lt; 1,000 mg 24hour urine collection Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No ongoing active infection No psoriasis porphyria No HIV positivity No significant traumatic injury within past 28 day No serious nonhealing wound , ulcer , bone fracture No peripheral sensory neuropathy &gt; grade 1 No hypertension control antihypertensive medication ( i.e. , blood pressure &gt; 150/100 mm Hg despite optimal medical therapy ) No cardiovascular disease , include follow : Unstable angina New York Heart Association class IIIV congestive heart failure History significant vascular disease ( e.g. , aortic aneurysm ) Symptomatic peripheral vascular disease within past 6 month Myocardial infarction within past 6 month Stroke within past 6 month No active malignancy within past 3 year , except curatively treat basal cell squamous cell carcinoma skin , carcinoma situ cervix , ductal lobular carcinoma situ breast , curatively treated malignancy evidence disease &gt; 3 year No retinal visual field change prior 4aminoquinoline compound therapy No known hypersensitivity 4aminoquinoline compound No know glucose6phosphate ( G6P ) deficiency No known bleed diathesis coagulopathy No known gastrointestinal pathology would interfere drug bioavailability No know prior hypersensitivity carboplatin , paclitaxel , bevacizumab , hydroxychloroquine , components No history abdominal fistula , gastrointestinal perforation , intraabdominal abscess within past 6 month No history gross hemoptysis ( i.e. , bright red blood ½ teaspoon ) within past 3 month No history social medical condition , investigator 's opinion , might interfere patient 's ability comply protocol pose additional unacceptable risk patient PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 2 week since prior radiation site brain , recover ≤ grade 1 At least 28 day since prior concurrent fulldose anticoagulant thrombolytic agent At least 28 day since prior major surgical procedure open biopsy anticipate need study therapy Vascular access device placement wound recovery allow study No prior cytotoxic chemotherapy target therapy advanced metastatic set No concurrent treatment rheumatoid arthritis systemic lupus erythematosus No concurrent combination antiretroviral therapy No concurrent hydroxychloroquine treatment prophylaxis malaria No concurrent aurothioglucose No concurrent investigational commercial agent therapy malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>